Risk factors
Corvus Pharmaceuticals (CRVS) risk factors
Item 1A of every Corvus Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks6 new4 dropped15 reworded
Corvus secured $189.4 million in a January 2026 offering, extending operations into the second quarter of 2028.
Filed Mar 12, 2026 - FY2024 10-K risk factors73 risks
Corvus Pharmaceuticals relies entirely on the clinical success and funding of its three main product candidates: soquelitinib, ciforadenant, and mupadolimab. The company has a going concern warning with $52.0 million in cash as of December 31, 2024. Heavy dependence on third-party manufacturers, clinical trial subjects, and key executives creates significant operational vulnerability.
Filed Mar 25, 2025